Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase Cβ
Authors:
- Anh T. Q. CongACAnh T. Q. Cong
- Taylor L. WitterTWTaylor L. Witter
- Sayantani Sarkar BhattacharyaSBSayantani Sarkar Bhattacharya
- Swaathi JayaramanSJSwaathi Jayaraman
- Jasper K. SolversonJSJasper K. Solverson
- Maria B. DuganMDMaria B. Dugan
- Jasmina PaluncicJPJasmina Paluncic
- Julia R. AlveyJAJulia R. Alvey
- Huy V. HuynhHHHuy V. Huynh
Open Access
- 21 May 2026
- journal article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
Protein kinase C (PKC) isozymes are ubiquitous kinases that direct diverse cellular pathways and are important drug targets for the treatment of cancer and neurological diseases. PKCs are auto-regulating enzymes governed by phospholipid and Ca 2+ signals via a mechanism that has remained enigmatic due to a paucity of structural information. Herein we present a series of structures of the full-length human PKCβI and PKCβII isozymes. These structures reveal the molecular basis by which PKCs maintain an auto-inhibited state, convert to a defined and ordered active conformation via a “lipid-lever” mechanism of allosteric activation, and how isoform-specific differences alter their allosteric regulatory mechanisms. We show that endoxifen, a recently identified PKCβI inhibitor, can alter the allosteric regulatory mechanism of PKCβI, providing a proof of concept for allosteric regulators of PKCs. Collectively, our data describe a foundational molecular model of second messenger-mediated allosteric regulation of PKCs that underpins PKC function, misregulation, and mechanisms of inhibition.Keywords
Funding Information
- National Institutes of Health (P50CA116201)
This publication has 75 references indexed in Scilit:
- Recombinant Topoisomerase 2 Production Using Cultured Human Cell Lines2025
- High‐efficiency recombinant protein purification using mCherry and YFP nanobody affinity matricesProtein Science, 2022
- Selectable high‐yield recombinant protein production in human cells using a GFP/YFP nanobody affinity supportProtein Science, 2018
- Polyphenol compounds and PKC signalingBiochimica et Biophysica Acta (BBA) - General Subjects, 2016
- Crystal Structure and Allosteric Activation of Protein Kinase C βIICell, 2011
- Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapyBreast Cancer Research and Treatment, 2010
- Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorderBioorganic & Medicinal Chemistry Letters, 2010
- A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimenInvestigational New Drugs, 2009
- Crystal structure of the Cys2 activator-binding domain of protein kinase Cδ in complex with phorbol esterCell, 1995
- The ζ Isoform of Protein Kinase C Controls Interleukin-2-Mediated Proliferation in a Murine T Cell Line: Evidence for an Additional Role of Protein Kinase C ϵ and βExperimental Cell Research, 1995